GR-1901

N/A

Report date: 2026/03/19 17:18:26

Base Information

Drug NameGR-1901
Drug Alias NameGR1901GR-1901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD123Anti-CD3
TargetsInterleukin-3 receptor subunit alphaT cell surface glycoprotein CD3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A